Eris Lifesciences Ltd (IN:ERIS)
:ERIS
Top Page
Eris Lifesciences Ltd
(ERIS)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹1,476.00
▼(-3.58% Downside)
Action:UpgradedDate:12/10/25
Eris Lifesciences Ltd demonstrates strong financial performance with robust revenue and cash flow growth, which significantly contributes to the overall score. The technical analysis shows a positive trend, though some bearish signals are present. The high P/E ratio and low dividend yield suggest overvaluation, impacting the valuation score.
Positive Factors
Sustained revenue growth
Consistent top-line growth and a notable year-over-year jump indicate expanding brand acceptance and market penetration in chronic therapy segments. Durable revenue expansion supports reinvestment in salesforce and new launches, strengthening mid‑term organic growth prospects.
Negative Factors
Free cash flow volatility
Variable free cash flow, despite improvements, can complicate multi-period capital allocation and reduce predictability for dividend policy, debt reduction or funding new launches. Persistent volatility may force reliance on external funding for strategic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained revenue growth
Consistent top-line growth and a notable year-over-year jump indicate expanding brand acceptance and market penetration in chronic therapy segments. Durable revenue expansion supports reinvestment in salesforce and new launches, strengthening mid‑term organic growth prospects.
Read all positive factors
Eris Lifesciences Ltd (ERIS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹185.93B
Dividend Yield0.47%
Average Volume (3M)2.07K
Price to Earnings (P/E)51.4
Beta (1Y)0.58
Revenue Growth20.02%
EPS Growth19.17%
CountryIN
Employees3,620
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)7.30
Shares Outstanding138,542,900
10 Day Avg. Volume1,915
30 Day Avg. Volume2,071
Financial Highlights & Ratios
PEG Ratio-5.23
Price to Book (P/B)6.64
Price to Sales (P/S)6.58
P/FCF Ratio20.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)42.7
Revenue Forecast (FY)₹32.02B
Eris Lifesciences Ltd Business Overview & Revenue Model
Company Description
Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, antidiabetes, anti-infective, antipyretics, vitamins/n...
How the Company Makes Money
Eris Lifesciences makes money mainly by selling branded pharmaceutical formulations (finished dosage medicines) to the Indian domestic market. Revenue is generated when prescriptions written by doctors translate into purchases by patients at retai...
Eris Lifesciences Ltd Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.86B | 28.79B | 19.91B | 16.62B | 13.26B | 11.93B |
| Gross Profit | 22.52B | 21.49B | 9.95B | 13.09B | 10.65B | 9.51B |
| EBITDA | 10.80B | 10.17B | 6.99B | 5.48B | 5.11B | 4.39B |
| Net Income | 4.16B | 3.52B | 3.92B | 3.82B | 4.06B | 3.55B |
Balance Sheet | ||||||
| Total Assets | 71.60B | 70.33B | 70.49B | 36.67B | 22.72B | 18.35B |
| Cash, Cash Equivalents and Short-Term Investments | 839.20M | 2.28B | 13.39B | 892.43M | 2.12B | 1.31B |
| Total Debt | 23.89B | 24.78B | 27.81B | 8.77B | 844.07M | 67.77M |
| Total Liabilities | 36.56B | 37.61B | 38.27B | 14.47B | 3.64B | 2.58B |
| Stockholders Equity | 30.91B | 28.54B | 25.86B | 21.96B | 19.08B | 15.76B |
Cash Flow | ||||||
| Free Cash Flow | 1.22B | 9.10B | 3.57B | -5.50B | 2.57B | 3.50B |
| Operating Cash Flow | 2.39B | 10.65B | 4.86B | 2.92B | 3.78B | 3.75B |
| Investing Cash Flow | -1.39B | -799.70M | -18.55B | -9.82B | -3.20B | -3.23B |
| Financing Cash Flow | -2.43B | -8.81B | 13.80B | 6.88B | -446.99M | -823.95M |
Eris Lifesciences Ltd Technical Analysis
Neutral
1530.85
Price Trends
1373.07
Negative
1472.85
Negative
1584.63
Negative
Market Momentum
-22.03
Negative
50.37
Neutral
69.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ERIS, the sentiment is Neutral. The current price of 1530.85 is above the 20-day moving average (MA) of 1328.86, above the 50-day MA of 1373.07, and below the 200-day MA of 1584.63, indicating a neutral trend. The MACD of -22.03 indicates Negative momentum. The RSI at 50.37 is Neutral, neither overbought nor oversold. The STOCH value of 69.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ERIS.
Eris Lifesciences Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹185.93B | 51.42 | ― | 0.47% | 20.02% | 19.17% | |
63 Neutral | ₹382.72B | 35.44 | ― | 2.16% | 4.17% | 41.51% | |
61 Neutral | ₹284.82B | 27.13 | ― | 1.07% | -1.51% | 14.27% | |
53 Neutral | ₹612.52B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ERIS
Eris Lifesciences Ltd
1,342.05
-48.85
-3.51%
IN:EMCURE
Emcure Pharmaceuticals Limited
1,653.60
579.27
53.92%
IN:GLAND
Gland Pharma Ltd.
1,728.75
188.05
12.21%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,259.20
-498.31
-18.07%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,170.50
665.44
44.21%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
4,088.55
-669.56
-14.07%
Eris Lifesciences Ltd Corporate Events
Eris Lifesciences inducts veteran banker Vineet Varma as independent director
Mar 14, 2026
Eris Lifesciences has appointed veteran banker Vineet Varma as an additional non-executive independent director for a five-year term starting 14 March 2026, following board approval based on the nomination and remuneration committee’s recomm...
Eris Lifesciences Posts Analyst Call Transcript for Q3 FY26
Feb 20, 2026
Eris Lifesciences Ltd has announced that the transcript of its analyst and investor conference call, held after the release of financial results for the quarter and nine months ended 31 December 2025, is now available on its website. The disclosur...
Eris Lifesciences Raises Stake to Make Swiss Parenterals Wholly Owned Unit via Preferential Share Allotment
Jan 16, 2026
Eris Lifesciences has allotted 2,306,372 fully paid equity shares of face value Re 1 each at an issue price of ₹1,835.35 per share on a preferential basis via private placement to investor Naishadh Shah, as consideration other than cash. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.